Dompé Farmaceutici S.p.a

This study tested an eye drop called cenegermin (Oxervate) in 85 adults with severe dry eye caused by Sjogren's syndrome. Participants also used cyclosporine eye drops. The goal was to see if cenegermin could increase tear production and reduce dry eye symptoms better than a plac…

This study followed 24 people with stage 1 neurotrophic keratitis, a rare eye condition where the cornea doesn't heal properly, to see if OXERVATE eye drops remain safe and effective over 30 months. Participants had already completed the earlier DEFENDO study. Researchers tracked…

This phase 2 trial tested whether adding reparixin to standard care helps adults with moderate to severe acute respiratory distress syndrome (ARDS) recover faster. The study enrolled 66 people on ventilators and measured changes in oxygen use and days off the ventilator. The goal…

This study tested an eye drop called OXERVATE in 37 adults with stage 1 neurotrophic keratitis, a condition where the cornea loses feeling and doesn't heal properly. The treatment was given for 8 weeks, and patients were followed for 24 weeks to see if the cornea healed safely. T…

This study tested whether a new eye drop containing a human protein (rhNGF) can help people with dry eye disease. 317 adults with moderate-to-severe dry eye used either the new drop or a placebo for 4 weeks. The goal was to see if the drops improve eye symptoms and increase tear …